MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-17-2026
Palatin Technologies ROCE Ratio 2011-2026 | PTN
Annual ROCE Ratio Palatin Technologies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 365.5 | 20176.44 | 1639.44 | -224.91 | -67.24 | -29.1 | 35.55 | 91.76 | -564.92 | 1673.64 | -78.15 | -161.28 | -67.72 | -976.63 | -74.34 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20176.44 | -976.63 | 1449.2 |
Quarterly ROCE Ratio Palatin Technologies
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1262.65 | 1367.49 | 217.31 | -366.52 | -1025.71 | -1076.94 | -497.48 | -573.6 | -65.88 | -89.76 | -213.89 | -302.03 | -253.77 | -243.59 | -156.8 | -100.2 | -87.45 | -77.08 | -66.1 | -48.18 | -38.21 | -30.75 | -30.26 | -22.8 | -22.73 | -40.44 | -61.75 | -79.46 | -96.77 | -42.32 | 172.3 | 226.74 | 437.09 | 465.7 | 334.84 | 357.97 | 240.69 | 12.6 | -102.84 | -260.0 | -427.38 | -251.34 | -184.75 | -57.55 | 48.25 | 17.48 | -14.86 | -54.3 | -82.99 | -70.27 | -56.51 | -228.72 | -394.9 | -413.19 | -425.25 | -257.67 | -90.45 | -22.37 | -20.35 | -18.51 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1367.49 | -1076.94 | -66.39 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M |  USA |
 |
Verastem
VSTM
|
-297.44 | $ 5.04 | -4.73 % | $ 349 M | USA |
 |
VistaGen Therapeutics
VTGN
|
-79.52 | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-28.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
-299.27 | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-92.73 | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-403.4 | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
-34.9 | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
-125.56 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
-30.68 | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-26.11 | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
-212.83 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-45.41 | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-66.51 | $ 1.05 | -3.67 % | $ 21.5 M | Israel |
 |
Enochian Biosciences
ENOB
|
903.05 | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Summit Therapeutics
SMMT
|
-56.92 | $ 16.58 | -3.94 % | $ 12.4 B | Britain |
 |
Zymeworks
ZYME
|
-86.57 | $ 24.18 | -2.07 % | $ 1.25 B | Canada |
 |
AbbVie
ABBV
|
-461.01 | $ 209.4 | -0.83 % | $ 370 B | USA |
 |
AbCellera Biologics
ABCL
|
-16.8 | $ 3.27 | -2.39 % | $ 977 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
-883.35 | - | -74.18 % | $ 955 K | USA |
 |
Altimmune
ALT
|
-42.02 | $ 3.02 | -5.63 % | $ 266 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-161.2 | $ 1.21 | -6.2 % | $ 309 M | Britain |
 |
Alnylam Pharmaceuticals
ALNY
|
63.56 | $ 317.36 | -3.29 % | $ 41.6 B | USA |
 |
Aytu BioScience
AYTU
|
-12.81 | $ 2.6 | -2.8 % | $ 16.3 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-49.83 | $ 4.29 | -3.6 % | $ 822 M | Canada |